TheTechno Optimist.

Anito-cel (anitocabtagene autoleucel)Kite Pharma (Gilead)—Gilead to acquire Arcellx for $7.8B

Kite Pharma (Gilead)

CAR-T cell therapy, BCMA, multiple myeloma

USGilead Sciences-ownedChecked 11 Oct

The brief

Analyst view
  • Gilead closed its Arcellx purchase on 28 April 2026: $115 a share in cash plus a $5 right paid if sales pass $6B by 2029.
  • Owning anito-cel outright ends the profit share, milestone and royalty payments to Arcellx.
Primer